Evaluation of pooling of samples for testing SARS-COV- 2 for mass screening of 1

2

COVID-19

- 3 4 5 6 7 Sally Mahmoud¹, Esra Ibrahim¹, Bhagyashree Thakre¹, Juliet Teddy¹, Preety Raheja¹, Subhashini Ganesan², Walid Zaher²
- 1. Biogenix G42 lab, Abu Dhabi, UAE
- 2. G42 Health care, Abu Dhabi, UAE
- Correspondence should be addressed to: Dr. Sally A. Mahmoud; sallyabdulla@gmail.com
- 8
- 9 Abstract
- Background 10

The current pandemic of SARS- COV- 2 virus, widely known as COVID-19 has affected 11 millions of people around the world. The World Health Organization (WHO) has 12 recommended vigorous testing to differentiate SARS-CoV-2 from other respiratory infections 13 14 to aid in guiding appropriate care and management. Situations like this have demanded robust testing strategies and pooled testing of samples for SARS- COV- 2 virus has provided the 15 solution to mass screening of people. The pooled testing strategy can be very effective in testing 16 with limited resources, yet it comes with its own limitations. These limitations need critical 17 consideration when it comes to testing of highly infectious disease like COVID -19. 18

19 Methods

20 The study evaluated the pooled testing of nasopharyngeal swabs for SARS- COV- 2 by 21 comparing sensitivity of individual sample testing with 4 and 8 pool sample testing. Median 22 cycle threshold (Ct) values were compared. The precision of pooled testing was assessed by doing an inter and intra assay of pooled samples. Coefficient of variance was calculated for 23 24 inter and intra assay variability.

25 Results

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

The sensitivity becomes considerably low when the samples are pooled, there is a higher percentage of false negatives with higher pool size and when the patient viral load is low or weak positive samples. High variability was seen in the intra and inter assay, especially in weak positive samples and larger pool size.

30 Conclusion

As COVID - 19 numbers are still high and testing capacity needs to be high, we have to meticulously evaluate the testing strategy for each country depending on its testing capacity, infrastructure, economic strength, and need to make a serious call on cost effective strategy of resource saving and risk/ cost of missing positive patients.

Key words: COVID-19; SARS-CoV-2; diagnosis; mass screening; sample pooling;

36 Background

The world in 2020 has been witnessing the most crippling pandemic on earth, ever since its outbreak in December 2019 at Wuhan, China. It is widely known as COVID-19, caused by SARS- COV- 2 virus, it's a new virus and not much has been known about the virus. From what is known the virus seems to exhibit a variable incubation period which can be up to 14 days and asymptomatic carriers can also transmit the virus, it spreads rapidly and affected large number of people than SARS and MERS, despite having lower case fatality rate. ¹ All these characteristics of the novel virus has made the containment and control of the virus challenging.

The World Health Organization (WHO) has recommended robust diagnostic testing to
differentiate SARS-CoV-2 from other respiratory infections to aid in guiding appropriate care
and management. Since the pandemic has affected millions of people, mass testing requires a
lot of resources. Further the WHO has suggested around 10 – 30 tests per Positive case as a

benchmark for adequate testing, it also has recommended a positive rate lower than 10% and
better if lower than 3%.²

In situations like this sample pooling can be a vital strategy to do testing in large numbers,
where sample extracts from a random number of samples from a heterogeneous population
group are combined into a single tube for pooled PCR analysis and this strategy have shown to
be cost–effective during mass testing compared with individual testing. ³

When the disease prevalence is less, it can be advantageous to pool individual samples into a single pool, this increases the test capacity and reduces the number of PCR tests. ^{4,5} For COVID-19, it has been estimated that pooling strategy reduces cost by 69% and use of tenfold fewer tests. ^{6,7} Recent research have also established the optimal pool size that maintains the testing accuracy for SARS-CoV-2 PCR and has found that accuracy is retained in a pool size of up to 32 samples. It has shown that costs can be reduced substantially without sacrificing accuracy. ⁸⁻¹⁰

However, when samples are diluted, there could be less viral genetic material available to detect and this increases in greater likelihood of false negative results. But studies establish that sample pooling will greatly increase the number of individuals that can be tested using less resource with a small reduction in sensitivity, which may be acceptable depending on the pooling efficiency ¹¹ Therefore, the FDA generally recommends that pooling test shows $\geq 85\%$ percent positive agreement when compared with the same test performed on individual samples.

In UAE, as of November 2020, there are around 1500 COVID -19 cases per 100K population
and UAE is in the top compared to other nations in the number of tests done per 100K
population. ¹² Around 149,000 tests are done per 100K population and the positive rate is 1%.

Figure 1]. With this background, the study aims to evaluate the pooling strategy for mass screening of COVID-19.
Aim
The aim of the study is to evaluate the pooling method for mass screening of COVID-19.
Objectives

• To evaluate the sensitivity of 4 and 8 sample pooling for testing COVID -19.

To study the repeatability and reproducibility of sample pooling by doing a inter and
 intra assay precision analysis

79

80 Materials and method

The samples for this study were collected from individuals using nasopharyngeal swabs and were transported to the viral transport medium (VTM). All methods were carried out in accordance with relevant guidelines and regulations. Then RNA extraction was done by the automated machine MGISP -960. After the RNA extraction, 10 microliters of the sample extract is added to 20 microliter of the master mix (BGI RT-PCR fluorescence KIT). Every plate has a positive control and a negative or blank control.

In individual sample extraction, 160 microliters of the sample were used in each well, for the
pooled sample 160 microlitre in each well was constituted by 40 microlitre of each sample in
4 fold pool sampling and 20 microlitre of each sample for 8 fold pool sampling.

90 Then the pooled samples are extracted following the RT- PCR procedure. VIC channel
91 represents the B-actin housekeeping gene as internal control while FAM channel represents the
92 ORF1ab gene for SARS-COV-2 virus detection. A positive test specimen is one for which VIC

- must have a cycle threshold (Ct) value \leq 32 and FAM Ct \leq 35, both fluorescence curves should be S shaped. A negative sample is one where there is no fluorescence curve at the FAM channel and a CT value of<32 and S shaped curve at the VIC channel.
- 96 If "S" shaped fluorescence curve is detected with a FAM Ct > 35, re-extraction is done and RT
- 97 PCR test is repeated, if a negative result is detected, it is reported negative and if "S" curve is
- 98 detected with a FAM Ct \leq 38 in re extraction results, then a positive report is given.

99 Sensitivity of pooled sample

For the sensitivity analysis, 40 known positive samples and 280 known negative samples were taken. In the 4-fold pool sample testing 40 known positive samples and 120 known negative samples were tested and in 8-fold pool sample testing, 40 known positive samples and 280 known negative samples were tested. Each well contained one known positive and 3 known negative samples in the 4pool method and each well contained one known positive and 7 known negative samples in the 8-pool sampling.

- 106 To analyse the sensitivity of sample of various viral load, out of the 40 samples used for pooling
- 107 , ten high viral load samples [HP] with Ct \leq 20, ten medium viral load samples [MP] with Ct >
- 108 20 to <30 and twenty low viral load or weak positives samples [WP] with Ct > 30 were used.
- 109 The sensitivity of the 4-pool sampling and 8 pool sampling was determined by running the 110 samples individually and the same samples were run in 4 and 8 pooled sample method and the 111 ability to detect the true positives were compared.

112 **Precision**

To assess the precision of pooled sample method intra and inter assay precision study wereconducted.

115 Intra assay precision

Intra assay precision was calculated by running 30 known positive samples in 4 pool and 8 pool sampling twice. 30 known positive samples were classified into three groups of 10 samples each based on the CT values as high viral load samples [HP] medium viral load samples [MP] and low viral load or weak positives samples [WP] as mentioned above.

All these samples were run twice, and the variability was assessed calculating the coefficientof variation (CoV %).

122

123 Inter assay precision

Inter assay precision was calculated by running 30 known positive samples, which was again classified into three groups based on the CT values as above. These samples were run on three consecutive days and the variability was assessed calculating the coefficient of variation (CoV %).

While doing the intra and inter assay experiment three known negative samples have been added to the same well along with one of the 30 known positive samples for 4 pool sample and seven known negative were added to the same pool along with one known positive for 8 pool sample .

132 **Results**

Our study showed that the sensitivity of 4 pooled sample was 75% and the sensitivity of 8 pooled sample was 62.5% (Table 1 and table 2). The sensitivity decreases from 75% in 4 pool sampling to 62.5% in 8 pool sampling. In the low viral load, weak positive samples (Ct value ≥ 35), sensitivity of 4 pool sample was 50% (Table 3) and it further reduces to 25% in 8 pool sampling with a false negative percentage as high as 75%. (Table 4)

The Ct difference was calculated between individual and pooled sample and the difference increased with the increase in pool size, the difference was more pronounced in the low viral load, weak positive group. (Table 5). The median Ct difference increased with increase in pool size and the maximum values were observed in weak viral load positive pooled samples. In the weak viral load positive sample pooling, the median became almost 0, as most samples turned negative with Ct value of 0 in the 8 pool of weak viral load positive sample. [Fig 2, 3,4]

Table 6, shows the discrepancies in results of the 40 positive samples, there were totally 15positive samples that missed detection after the samples were pooled.

The % CV (Coefficient of variance) ranged from 0 - 4% in intra and inter assay of 4 pool samples of high and medium viral load positive samples, however inter assay of 8 pool sample and weak positive samples of 4 pool and 8 pool both inter and intra assay were very high (Table 7 and Table 8)

150 Discussion

Our study showed that the strategy of pooling of samples for COVID-19 RT-PCR, has lower 151 sensitivity than the standard individual RT-PCR and the sensitivity decreases with the increase 152 in the pool size. Further when weak viral load positive samples were pooled the sensitivity 153 became as low as 25%, which leads to increased false negatives. Similar studies have reported 154 varied results, some studies have claimed pooling to be an effective strategy, a study done in 155 Malaysia showed that pools of 10 samples were similar in sensitivity compared to individual 156 testing. ¹⁴ A study in UK, has strongly supported pooled approach and reports a clinically 157 insignificant sensitivity loss when samples are pooled and false positive rate up to 5.3%.¹⁵ But 158 159 another study done in Spain evaluating the sensitivity of pooled samples, testing various

solutions and VTM showed that the sensitivity varied from 62.5 % to 81% and false negatives
were as high as up to 40 %. ¹⁶

The study also showed that the pooling resulted in a median loss of 2.29 Ct for high viral load 162 positive 4 -pool samples to median loss of -36.01 Ct in 8 - pool low viral load positive 163 samples, this is because the samples became negative with Ct value 0, after 8 sample pooling. 164 This shows that in low viral load/ weak positive pooled samples the cycle threshold increased, 165 166 or most samples went undetected. A study in Kenya also showed that the cycle threshold values were higher for samples which were pooled then tested individually.¹⁷ The study in Spain also 167 showed that sample dilution in pooling strategy resulted in a median loss of 2.8 to 3.3 Ct and 168 thereby drop in sensitivity.¹⁸ 169

The coefficient of variation was high among the low viral load positive samples both in the inter and intra assay, this shows the high variability in the results when the samples are pooled. Higher Ct values in sample pooling method might be due to the inadequacy of samples when they are pooled and lower Ct values in pool testing might be due to the carrier effect of the higher RNA content in the pool. There is not much studies that have commented on %CV variability pertaining to COVID-19 testing.¹⁹

When a person shows a weak positive result, that means that the viral load is low, so we need to amplify it several more times to detect the virus, hence the high Ct value. This kind of weak positives may be a of result of sample inadequacy or the person is in early/ late stage of infection where the viral load is low. These samples are missed detection when they are pooled. Such weak positive samples may pose a significant threat of spreading the infection to others. Studies on the clinical significance of low viral load positive cases are needed, and it remains a question of whether it is safe to miss detection of such cases?

Pooling samples can be very challenging logistically, usually in pool testing if a pooled sample 183 tests negative, then all samples within that pool are deemed negative and if a pool tests positive. 184 then individual samples making up that pool are tested again as individual samples to identify 185 the positives. Hence the larger the pool the more challenging is the deconvolution. ²⁰ Further 186 there is additional time required in deconvoluting larger pools, which leads to time delay in 187 reporting and this becomes crucial in severely ill patients and the high-risk contacts where early 188 reporting is requisite. ²¹ Not to neglect the anxiety caused by isolation in patients included in 189 the positive sample pools, until retesting of the individual samples is completed. 190

A lot of factors affect the sensitivity of RT-PCR, like the sensitivity of the kit, dilution used, 191 the techniques of sample collection, type of samples (NPS vs oropharyngeal vs nasal etc), 192 sample transport temperature, viral load in the sample which varies according to the stage of 193 infection. ^{22,23} Therefore RT- PCR of sample pooling strategy has its own limitations, it cannot 194 ensure the diagnostic integrity of the individual sample, ²⁴ it can mask the technical errors like 195 insufficient sampling, ^{19,25} it has higher percentage of false negatives, ¹⁰ reduces sensitivity ²⁶ 196 and sample dilution has led to the risk of missing weak viral load or borderline positive 197 samples ^{17,21} Although pooling of samples facilitates rational use of resources, it might miss 198 individuals who might be positive for COVID-19. ^{27,28} 199

This information becomes crucial for deciding the pooled strategy testing for disease like COVID -19. In the current pandemic, we simply can't afford to miss any positive cases. With the high Ro value around 3 for SARS-COV-2, ²⁹ every missed positive case can lead to rapid spread of infection to others.

204 Limitations

Our study was conducted in a single laboratory in a defined geographical area, more studies and data are needed to validate sample pooling strategies and the clinical significance and threat of communicability of weak positive samples.

208 Conclusion

209 Based on the study results, we conclude that pooled testing strategy misses low viral load/ weak 210 positive COVID – 19 cases and there is high variability in results when the samples are pooled. 211 While in a low resource setting, where pooled sample testing is better than not having any kind 212 of testing, sample pooling might be an effective way for mass screening and the increase in percentage of false negative tests may be dismissed, but caution is advised and it needs careful 213 scrutiny. In the current scenario of the pandemic, validation studies on the cost-effective 214 analysis of pooling samples should be done, considering the cost and risk of missing even a 215 single positive person. As COVID - 19 numbers are still high and testing capacity needs to be 216 217 high, we have to meticulously evaluate the testing strategy of each country depending on its testing capacity, infrastructure, economic strength, and need to make a serious call on cost 218 effective strategy of resource saving and cost of missing positive patients. 219

220 Declarations

221 Ethics approval and consent to participate

222 The Ethics approval was obtained from Department of Health (DOH) Institutional review223 board (IRB), Abu Dhabi

All methods were carried out in accordance with relevant guidelines and regulations. The
Department Of Health (DOH) Institutional review board (IRB), Abu Dhabi

- has waived off the consent as it does not use any participant data/ information, the lab data on
- the viral samples were only used for this study
- 228 Consent for publication Not applicable
- 229 Data Availability
- 230 The data is available with the corresponding author, Dr. Sally, Director of Biogenix G42 lab
- and will be produced on request
- 232 Competing interests
- 233 The authors declare that they have no competing interests regarding the publication of this
- 234 paper

235 Funding statement

The study was not funded by any funding body, it was done in Biogenix lab as a part of research

237 Authors' contribution

- 238 SM conception, design of work, acquisition, analysis, interpretation of data, drafted and
- 239 substantively revised the manuscript
- EI conception, design of work, acquisition, analysis, interpretation of data, drafted and
- substantively revised the manuscript
- BT- conception, design of work, interpretation of data, drafted and substantively revised themanuscript
- JT- conception, design of work, interpretation of data, drafted and substantively revised themanuscript

246	PR- conception, design of work, drafted and substantively revised the manuscript
247	SG-Acquisition, analysis, interpretation of data, drafted and substantively revised the
248	manuscript
249	WA- conception, drafted and substantively revised the manuscript
250	Acknowledgments
251	We acknowledge all lab personnel, skilled technicians who provided help during the research
252	and preparation of the manuscript
253	References
254	1. Mahase Elisabeth. Coronavirus: covid-19 has killed more people than SARS and
255	MERS combined, despite lower case fatality rate BMJ 2020; 358 :m461
256	2. WHO. COVID-19 - virtual press conference - 30 March 2020. Available at:
257	https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-
258	emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2
259	3. Deckert, Barnighausen, NA Kyei. Simulation of pool sampling analysis strategy for
260	COVID – 19 mass testing. Bulletin of the World Health Organization 2020;98:590-598.
261	Available at: https://www.who.int/bulletin/volumes/98/9/20-257188/en/
262	4. Hogan CA, Sahoo MK, Pinsky BA. Sample pooling as a strategy to detect community
263	transmission of SARS-CoV-2. JAMA. 2020. https://doi.org/10.1001/jama.2020.5445.
264	5. Cherif A, Grobe N, Wang X, Kotanko P. Simulation of Pool Testing to Identify Patients
265	With Coronavirus Disease 2019 Under Conditions of Limited Test Availability. JAMA
266	Network Open. 2020;3(6):e2013075.

267	6.	Abdalhamid B, Bilder CR, McCutchen EL, Hinrichs SH, Koepsell SA, Iwen PC.
268		Assessment of specimen pooling to conserve SARS CoV-2 testing resources. Am J Clin
269		Pathol. 2020;153(6):715–8.
270	7.	Verdun CM, Fuchs T, Harar P, Elbrächter D, Fischer DS, Berner J, Grohs P, Theis FJ,
271		Krahmer F. Group testing for SARS-CoV-2 allows for up to 10-fold efficiency increase
272		across realistic scenarios and testing strategies. medRxiv. 2020
273	8.	Ben-Ami R, Klochendler A, Seidel M, Sido T, Gurel-Gurevich O, Yassour M, et al.
274		Large-scale implementation of pooled RNA-extraction and RT-PCR for SARS-
275		CoV-2 detection [preprint]. Cold Spring Habor: medRxiv; 2020. Available
276		from: https://www.medrxiv.org/content/10.1101/2020.04.17.20069062v2 [cited
277		2020 Nov 12].
278	9.	Schmidt M, Hoehl S, Berger A, Zeichhardt H, Hourfar K, Ciesek S, et al. FACT –
279		Frankfurt adjusted COVID-19 testing - a novel method enables high-throughput
280		SARS-CoV-2 screening without loss of sensitivity [preprint]. Cold Spring Habor:
281		medRxiv; 2020. Available
282		from: https://www.medrxiv.org/content/10.1101/2020.04.28.20074187v1 [cited
283		2020 Nov 12].
284	10	. Yelin I, Aharony N, Shaer Tamar E, Argoetti A, Messer E, Berenbaum D, et al.
285		Evaluation of COVID-19 RT-qPCR test in multi-sample pools. Clin Infect Dis. 2020
286		May 2;ciaa531. <u>http://dx.doi.org/10.1093/cid/ciaa531</u> pmid: <u>32358960</u>
287	11	FDA. USA. Pooled sample testing and screening testing for COVID-19. Available at:
288		https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-
289		devices/pooled-sample-testing-and-screening-testing-covid-19

290	12. Federal Competitiveness and Statistics centre. FCSA. UAE Ministry of Cabinet Affairs.
291	Available at: https://fcsa.gov.ae/en-us/Pages/Covid19/UAE-Covid-19-Updates.aspx
292	13. Our World in Data. United Arab Emirates. Coronavirus pandemic country profile.
293	Available at: <u>https://ourworldindata.org/coronavirus/country/united-arab-</u>
294	emirates?country=~ARE
295	14. Lim KL, Johari NA, Wong ST, Khaw LT, Tan BK, Chan KK, Wong SF, Chan WL,
296	Ramzi NH, Lim PK, Hakim SL. A novel strategy for community screening of SARS-
297	CoV-2 (COVID-19): Sample pooling method. PloS one. 2020 Aug 28;15(8):e0238417.
298	15. Iacobucci G. Covid-19: Study findings strongly support use of pooled testing, say
299	researchers. BMJ 2020;371:m4267
300	16. Alcoba-Florez J, Gil-Campesino H, de Artola DG, González-Montelongo R,
301	Valenzuela-Fernández A, Ciuffreda L, Flores C. Sensitivity of different RT-qPCR
302	solutions for SARS-CoV-2 detection. International Journal of Infectious Diseases. 2020
303	Oct 1;99:190-2.
304	17. Agoti, Charles & Mutunga, Martin & Lambisia, Arnold & Kimani, Domtila &
305	Cheruiyot, Robinson & Kiyuka, et al. Pooled testing conserves SARS-CoV-2
306	laboratory resources and improves test turn-around time: experience on the Kenyan
307	Coast. Wellcome Open Research. 5. 186. 10.12688/ wellcomeopenres.16113.1.
308	18. de Salazar A, Aguilera A, Trastoy R, et al. Sample pooling for SARS-CoV-2 RT-PCR
309	screening [published online ahead of print, 2020 Sep 10]. Clin Microbiol Infect.
310	2020;S1198-743X(20)30537-1.
311	19. Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner B, Becker SL,
312	Schneitler S, Smola S. Pooling of samples for testing for SARS-CoV-2 in asymptomatic
313	people. The Lancet Infectious Diseases. 2020 Apr 28.

- 20. Ball J, McNally A. Pooled testing for SARS-CoV-2 could provide the solution to UK's
 testing strategy. bmj. 2020 Nov 9:371:m4312
- 21. Mishra B, Behera B, Mohanty M, Ravindra A, Ranjan J. Challenges and issues of
- 317 SARS-CoV-2 pool testing. Lancet Infect Dis. 2020 Nov;20(11):1233. doi:
- 318 10.1016/S1473-3099(20)30463-1. Epub 2020 Jul 14. PMID: 32679083.
- 22. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P,
- del Campo R, Ciapponi A, Sued O, Martinez-Garcia L, Rutjes A, Low N, Perez-
- 321 Molina JA. False-negative results of initial RT-PCR assays for COVID-19: a
- 322 systematic review. medRxiv. 2020 Jan 1.
- 323 23. Afzal A. Molecular diagnostic technologies for COVID-19: Limitations and
- 324 challenges. J Adv Res. 2020 Nov;26:149-159. doi: 10.1016/j.jare.2020.08.002. Epub
- 325 2020 Aug 6. PMID: 32837738; PMCID: PMC7406419.
- 326 24. CDC. Interim Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic,
- 327 Screening, and Surveillance Testing. Available at :
- 328 https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html
- 329 25. Mishra B, Behera B, Mohanty M, Ravindra A, Ranjan J. Challenges and issues of
- 330 SARS-CoV-2 pool testing. The Lancet Infectious Diseases. 2020 Nov 1;20(11):1233.
- 26. Pikovski A, Bentele K. Pooling of coronavirus tests under unknown prevalence.
- Epidemiology & Infection. 2020;148.
- 27. Abdalhamid B, Bilder CR, Garrett JL, Iwen PC (2020) Cost Effectiveness of Sample
- Pooling to Test for SARS-CoV-2. J Infect Dev Ctries 14:1136-1137. doi:
- 335 10.3855/jidc.13935
- 28. Centers for Disease Control and Prevention. *Evaluating and testing persons for coronavirus disease 2019 (COVID-19). Updated March 24, 2020. Accessed March 25*
- 338 2020. <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html</u>

- 29. D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction
 number, *R*₀, based on the early phase of COVID-19 outbreak in Italy. Biosaf Health.
 2020 Jun;2(2):57-59. doi: 10.1016/j.bsheal.2020.03.004. Epub 2020 Apr 2. PMID:
 32835209; PMCID: PMC7148916.
- 343
- 344

345 **Table 1: Sensitivity of 4 sample pooling**

Pooling method Standard method (Individual sample run)			1)
	Positive	Negative	Total
Positive	30	0	30
Negative	10	0	10
Total	40		40

- 346 Sensitivity-75% (CI 61.7% 88.3%)
- 347 False negative percentage -25%

348 Table 2: Sensitivity of 8 sample pooling

Pooling method	Standard method		
	Positive	Negative	Total
Positive	25	0	27
Negative	15	0	13
Total	40		40

- 349 Sensitivity 62.5% (CI 47.5% 77.5%)
- 350 False negative percentage -37.5%

Table 3: Sensitivity of 4 sample pooling of 20 weak positive samples with Ct value more

352 than 35

Pooling method Standard method			
	Positive	Negative	Total
Positive	10	0	30
Negative	10	0	10
Total	20		40

353

- 354 Sensitivity- 50 % (CI 28.09 % 71.91%)
- **355** False negative percentage -50%

Table 4 : Sensitivity of 8 sample pooling of 20 weak positive samples with Ct value more

357 than 35

Pooling method	Standard method		
	Positive	Negative	Total
Positive	5	0	5
Negative	15	0	15

-			
	Total	20	20
	Total	20	20
L			

358

- Sensitivity 25 % (CI 6.03 % 43.97%) 359
- 360 False negative percentage - 75%

Table : 5 Median Ct difference between individual and pooled samples 361

Pool details	Ct difference (Median)	Interquartile range (IQR)
4 pool (HP)	2.29	0.49
4 pool (MP)	1.79	0.79
4 pool (WP)	- 18.26	39.60
8 pool (HP)	3.10	1.38
8 pool (MP)	2.66	1.21
8 pool (WP)	-36.01	28.81

362

* HP – High viral load positive sample, MP- Medium viral load positive sample, WP- low 363

viral load/ weak positive sample 364

Table 6: Test result discrepancies in pool sample testing 365

Samples	Original	4 pool testing	8 pool testing			
High viral l	High viral load positive samples (HP)					
1	Positive	Positive	Positive			
2	Positive	Positive	Positive			
3	Positive	Positive	Positive			

4	Positive	Positive	Positive
5	Positive	Positive	Positive
6	Positive	Positive	Positive
7	Positive	Positive	Positive
8	Positive	Positive	Positive
9	Positive	Positive	Positive
10	Positive	Positive	Positive
Medium	viral load positive s	ample (MP)	
11	Positive	Positive	Positive
12	Positive	Positive	Positive
13	Positive	Positive	Positive
14	Positive	Positive	Positive
15	Positive	Positive	Positive
16	Positive	Positive	Positive
17	Positive	Positive	Positive
18	Positive	Positive	Positive
19	Positive	Positive	Positive
20	Positive	Positive	Positive
Low vira	al load// weak positiv	e samples (WP)	
<mark>21</mark>	Positive	Negative	Negative
22	Positive	Positive	Positive
23	Positive	Positive	Positive
24	Positive	Positive	Positive
<mark>25</mark>	Positive	Negative	Negative

<mark>26</mark>	Positive	Negative	Negative
<mark>27</mark>	Positive	Negative	Negative
<mark>28</mark>	Positive	Positive	Negative
<mark>29</mark>	Positive	Negative	Negative
<mark>30</mark>	Positive	Positive	Negative
<mark>31</mark>	Positive	Negative	Negative
<mark>32</mark>	Positive	Negative	Negative
33	Positive	Positive	Positive
<mark>34</mark>	Positive	Negative	Negative
35	Positive	Positive	Positive
<mark>36</mark>	Positive	Negative	Negative
<mark>37</mark>	Positive	Positive	Negative
<mark>38</mark>	Positive	Positive	Negative
<mark>39</mark>	Positive	Positive	Negative
<mark>40</mark>	Positive	Negative	Negative

366

Table 7: Intra and inter assay of 4 pooled sampling 367

	Coefficient of Variation %
Intra assay	
High viral load positive samples	0-2%
Medium viral load positive samples	0 - 2%
Low viral load/ Weak positives	2 - 141 %
Inter assay	

High viral load positive samples	1-2%
Medium viral load positive samples	1-4%
Low viral load/ Weak positives	1- 173%

368

Table 8 : Intra and inter assay of 8 pooled sampling 369

	Coefficient of Variation %	
Intra assay		
High viral load positive samples	0 - 4%	
Medium viral load positive samples	0-3%	
Low viral load/ Weak positives	2-141%	
Inter assay		
High viral load positive samples	2-14%	
Medium viral load positive samples	2-87 %	
Low viral load/ Weak positives	26-173%	

Fig 1: Shows the number of COVID – 19 tests done per 1000 people ¹³ 370






Figure 2: The Ct values of High viral load positive (HP) samples






Figure 3 : The Ct values of Medium viral load positive(MP) samples






Figure 4: The Ct values of low viral load / weak positive (WP) samples

